Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date of Report: April 4, 2025
Event: Presentation of first-in-human clinical trial data for ARV-102, an investigational PROTAC LRRK2 degrader, at the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2025) in Vienna, Austria.
Key Financial Metrics
This filing is a current report regarding clinical trial data and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Findings
The report details the results of a Phase 1 healthy volunteer trial for ARV-102, designed to assess safety, pharmacokinetics, and pharmacodynamics.
- Safety Profile: ARV-102 was well tolerated. No serious adverse events were reported in Single Ascending Dose (SAD) or Multiple Ascending Dose (MAD) cohorts. Primary treatment-related adverse events were headache (17.1% of treated vs. 0% placebo) and fatigue (8.6% of treated vs. 25% placebo).
- Pharmacokinetics: Median maximum concentration occurred 6 hours post-dose. Plasma half-life was 73 hours. Drug levels in cerebrospinal fluid (CSF) increased in a dose-dependent manner.
- Pharmacodynamics:
- LRRK2 Degradation: >90% reduction in peripheral blood mononuclear cells at single doses ≥60 mg and repeated doses ≥20 mg.
- CSF Penetration: >50% LRRK2 reduction in CSF at single doses ≥60 mg and repeated doses ≥20 mg.
- Downstream Engagement: >50% decrease in peripheral phospho-Rab10 T73 (biomarker for LRRK2 activity) at single doses ≥30 mg.
Outlook, Risks, and Management Commentary
Management highlighted that the data signifies brain penetration, substantial central and peripheral LRRK2 protein degradation, and downstream pathway engagement. The SAD cohort is completed as of the March 13, 2025 data cutoff, while the MAD cohort remains ongoing. The filing notes that specific data for certain endpoints in the MAD cohort is pending.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical tables and specific adverse event descriptions.
- Confirm the timeline for the completion of the MAD cohort and the release of pending pharmacodynamic data.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Assess the competitive landscape for LRRK2 degraders in Parkinson's disease and progressive supranuclear palsy.